Inventor · disambiguated record
Adam Savitz
Also filed as: SAVITZ ADAM
12 granted patents·22 pending applications·21 citations·filing 2017–2025
86Inventor score
Top patents by PatentIndex Score
34 records- 0196US11266627B1Compositions and methods for the treatment of depressionJANSSEN PHARMACEUTICALS INC·Filed 2021·Granted Mar 8, 2022·12 cites·30 claims
- 0295US11998525B2Compositions and methods for the treatment of depressionJANSSEN PHARMACEUTICALS INC·Filed 2023·Granted Jun 4, 2024·5 cites·29 claims
- 0394US12150929B2Compositions and methods for the treatment of depressionJANSSEN PHARMACEUTICALS INC·Filed 2024·Granted Nov 26, 2024·2 cites·19 claims
- 0493US12161622B2Compositions and methods for the treatment of depressionJANSSEN PHARMACEUTICALS INC·Filed 2022·Granted Dec 10, 2024·2 cites·29 claims
- 0588US12419859B2Compositions and methods for the treatment of depressionJANSSEN PHARMACEUTICALS INC·Filed 2024·Granted Sep 23, 2025·0 cites·7 claims
- 0680US12171743B2Forms of aticaprantJANSSEN PHARMACEUTICALS INC·Filed 2024·Granted Dec 24, 2024·0 cites·30 claims
- 0778US12233059B2Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Granted Feb 25, 2025·0 cites·20 claims
- 0877US12201610B2Compositions comprising aticaprantJANSSEN PHARMACEUTICALS INC·Filed 2024·Granted Jan 21, 2025·0 cites·19 claims
- 0977US2025326714A1Pure forms of crystalline aticaprantJANSSEN PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1076US2025325515A1Forms Of AticaprantJANSSEN PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1175US12208096B2Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Granted Jan 28, 2025·0 cites·12 claims
- 1275US11998524B2Forms of aticaprantJANSSEN PHARMACEUTICALS INC·Filed 2023·Granted Jun 4, 2024·0 cites·44 claims
- 1372US12226375B1Method of treatment and selection of patients benefiting from agomelatine based on EEG measurementsALTO NEUROSCIENCE INC·Filed 2024·Granted Feb 18, 2025·0 cites·17 claims
- 1470US2025009738A1Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 1569US2024307377A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 1667US2025177350A1Compositions and methods for the treatment of depressionJANSSEN PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1767US2023277500A1Compositions comprising aticaprantJANSSEN PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1865US2023301573A1Methods of Identifying Schizophrenia Patients At Risk for RelapseJANSSEN PHARMACEUTICA NV·Filed 2023·Application pending·0 cites
- 1964US2024307376A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 2064US2025144092A1Treatment of psychiatric or neurological disorders in patients with prominent anhedonia using irdabisant as a monotherapy or in combination with an antipsychotic agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 2163US2024316016A1Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 2262US2025120957A1Treatment of neuropsychiatric disorders with tilivapramALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 2361US2023348377A1Pure forms of crystalline aticaprantJANSSEN PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2461US2024342165A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 2561US2024307378A1Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 2659US2024197721A1Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2023·Application pending·0 cites
- 2759US2024238245A1Compositions and methods for the treatment of depressionJANSSEN PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2859US2025228819A1Compositions comprising aticaprantJANSSEN PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2958US2024342164A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2024·Application pending·0 cites
- 3058US2025177387A1Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2025·Application pending·0 cites
- 3155US2025177386A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2025·Application pending·0 cites
- 3254US2022387424A1Method of treatment of depressed patients with poor cognition and selection of other patients benefiting from a benzylpiperazine-aminopyridine agentALTO NEUROSCIENCE INC·Filed 2022·Application pending·0 cites
- 3352US11723569B2Methods of identifying schizophrenia patients at risk for relapseJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Aug 15, 2023·0 cites·20 claims
- 3452US2025177331A1Method of treatment and selection of patients benefiting from agomelatine based on eeg measurementsALTO NEUROSCIENCE INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Adam Savitz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →